Aptadir
Private Company
Funding information not available
Overview
Aptadir is a preclinical-stage biotech leveraging a novel RNA-based platform to target DNA methylation, a key epigenetic driver of disease. The company's technology offers two modalities: global DNMT1 inhibition (aptaDiR) and locus-specific targeting (captaDiR), aiming for greater specificity and reduced toxicity compared to existing epigenetic drugs. With a seasoned leadership team and scientific founders from prestigious institutions, Aptadir is positioned to address high-need areas in oncology and rare diseases. The company is currently in the preclinical research phase, building its pipeline for untreatable cancers.
Technology Platform
RNA-based platform using modified oligonucleotides (aptamers) to selectively inhibit DNA methyltransferase 1 (DNMT1). Includes two modalities: 'aptaDiR' for global DNMT1 sequestration without toxicity, and 'captaDiR' for locus-specific inhibition by fusing the aptamer to a gene-targeting sequence.
Opportunities
Risk Factors
Competitive Landscape
Aptadir competes in the epigenetic drug space against approved non-specific DNMT1 inhibitors (azacitidine, decitabine) and a pipeline of new modalities from other biotechs. Its key differentiator is the potential for gene-specific demethylation using RNA, which, if proven, could offer a unique precision medicine approach compared to global epigenetic modifiers.